ASGCT 2025 - In vivo generated CAR-T using T cell-targeting Lentivirus vectors shows high tumor control efficacy in a PBMC-humanized model
Read Flipbook
From our cutting-edge immuno-safety assay for CRS risk detection, to the largest collection of neurodegenerative transgenic models and 400+ human iPSC lines — we’re here to help de-risk and accelerate the development of your gene and cell therapies. Check out these resources to learn more about solutions we offer and don't forget to schedule a meeting so we can help tailor those solutions to you!
Error - something went wrong!
Would you like to schedule a discussion with the JAX team at ASGCT?
Thank you! We will be in touch soon.